

SEATTLE GENETICS INC /WA
Form 8-K
November 02, 2012

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

Current Report Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): October 30, 2012

Seattle Genetics, Inc.

(Exact name of Registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

0-32405
(Commission

File Number)
21823 30th Drive SE

Bothell, Washington 98021

91-1874389
(I.R.S. Employer

Identification No.)

Edgar Filing: SEATTLE GENETICS INC /WA - Form 8-K

(Address of principal executive offices, including zip code)

(425) 527-4000

(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

(b) On October 30, 2012, Thomas C. Reynolds, M.D., Ph.D., Chief Medical Officer of Seattle Genetics, Inc. (Seattle Genetics or the Company), informed the Company of his resignation in connection with his retirement for a family health matter. Dr. Reynolds will continue to serve as the Company's Chief Medical Officer until December 31, 2012. Dr. Reynolds has been a key contributor at Seattle Genetics, notably through his leadership of the Company's clinical and regulatory teams during the development and approval of ADCETRIS. The Company has started a search for a replacement to Dr. Reynolds and anticipates a seamless transition of responsibilities over the next several months.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SEATTLE GENETICS, INC.

Date: November 2, 2012

By: /s/ Eric L. Dobmeier
Eric L. Dobmeier

Chief Operating Officer